Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Witkin

Showing results (241-250 of 321) with videos related to

Pageof 33
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|March 13, 1998
Reversal of behavioral effects of pentylenetetrazol by the neuroactive steroid ganaxoloneM Beekman, J T Ungard, M Gasior, et al.
Therapeutic Drug Monitoring|January 1, 1979
Determination of 5-(p-hydroxyphenyl)-5-phenylhydantoin and studies relating to the disposition of phenytoin in manK M Witkin, D L Bius, B L Teague, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1988
Behavioral studies with anxiolytic drugs. V. Behavioral and in vivo neurochemical analyses in pigeons of drugs that increase punished respondingR S Mansbach, C Harrod, S M Hoffmann, et al.
Neuropharmacology|March 16, 2001
Increased expression of neuronal Src and tyrosine phosphorylation of NMDA receptors in rat brain after systemic treatment with MK-801A Lindén, M Storvik, M Lakso, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 9, 2004
Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907]J M Witkin, D Dijkstra, B Levant, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 19, 2005
Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behaviorGregory T Collins, Jeffrey M Witkin, Amy H Newman, et al.
Heliyon|January 15, 2024
KRM-II-81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsyJodi L Smith, Jeremy Wertz, Arnold Lippa, et al.
Psychopharmacology|February 14, 2006
In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disordersAndrew Alt, Brianne Weiss, Ann Marie Ogden, et al.
Pharmacology, Biochemistry, and Behavior|February 12, 2021
Rapid tolerance to behavioral effects of ethanol in rats: Prevention by R-(-)-ketamineHana Shafique, Jeffrey M Witkin, Jodi L Smith, et al.
International Journal of Molecular Sciences|June 27, 2024
(<i>R</i>)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological DisordersHana Shafique, Julie C Demers, Julia Biesiada, et al.
Pageof 33

Showing results (241-250 of 321) with videos related to

Sort By:
Pageof 33
The Journal of Pharmacology and Experimental Therapeutics|March 13, 1998
Reversal of behavioral effects of pentylenetetrazol by the neuroactive steroid ganaxoloneM Beekman, J T Ungard, M Gasior, et al.
Therapeutic Drug Monitoring|January 1, 1979
Determination of 5-(p-hydroxyphenyl)-5-phenylhydantoin and studies relating to the disposition of phenytoin in manK M Witkin, D L Bius, B L Teague, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1988
Behavioral studies with anxiolytic drugs. V. Behavioral and in vivo neurochemical analyses in pigeons of drugs that increase punished respondingR S Mansbach, C Harrod, S M Hoffmann, et al.
Neuropharmacology|March 16, 2001
Increased expression of neuronal Src and tyrosine phosphorylation of NMDA receptors in rat brain after systemic treatment with MK-801A Lindén, M Storvik, M Lakso, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 9, 2004
Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907]J M Witkin, D Dijkstra, B Levant, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 19, 2005
Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behaviorGregory T Collins, Jeffrey M Witkin, Amy H Newman, et al.
Heliyon|January 15, 2024
KRM-II-81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsyJodi L Smith, Jeremy Wertz, Arnold Lippa, et al.
Psychopharmacology|February 14, 2006
In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disordersAndrew Alt, Brianne Weiss, Ann Marie Ogden, et al.
Pharmacology, Biochemistry, and Behavior|February 12, 2021
Rapid tolerance to behavioral effects of ethanol in rats: Prevention by R-(-)-ketamineHana Shafique, Jeffrey M Witkin, Jodi L Smith, et al.
International Journal of Molecular Sciences|June 27, 2024
(<i>R</i>)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological DisordersHana Shafique, Julie C Demers, Julia Biesiada, et al.
Pageof 33